RAP-219 Clears Phase 2 With a Modest, Tolerable Mania Signal

Company Rapport Therapeutics Event Type Phase 2 Topline Results Modality Small molecule; TARPγ8-selective AMPA receptor negative allosteric modulator Asset RAP-219 Target AMPA receptors associated with TARPγ8 Disease Area Acute bipolar mania (bipolar I disorder) Summary Rapport Therapeutics reported that RAP-219 met the primary endpoint in…